Приготовление образцов опухолей, залитых формалином и парафином: протокол сохранения образцов тканей и цитологических образцов немелкоклеточного рака легкого (НМРЛ)

Executive Industry Relevance

This protocol enables reliable preservation of NSCLC tissue and cytology samples, supporting downstream biomarker analysis such as PD-L1 immunohistochemistry. Standardized formalin fixation and paraffin embedding ensure sample integrity for histopathological evaluation, which is critical for target validation in immuno-oncology drug development. The method facilitates consistent sectioning and staining, enabling reproducible microscopic assessment across discovery and preclinical workflows.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Preserves tumor morphology and antigenicity for accurate biomarker assessment in NSCLC models.
• Operational Value: Enables parallel processing of tissue and cytology specimens from the same patient cohort.

Screening & Assay Development

• Scientific Value: Produces uniform sections suitable for immunohistochemical staining and quantitative image analysis.
• Operational Value: Supports assay standardization by minimizing pre-analytical variability in sample preparation.

Translational & Preclinical Research

• Scientific Value: Maintains cytological architecture from bronchial washes, enabling correlation between liquid biopsies and tissue biomarkers.
• Operational Value: Provides a standardized workflow for biobanking NSCLC specimens across research sites.

Pipeline & Workflow Integration

The method integrates into NSCLC discovery pipelines by enabling histopathological confirmation of target expression prior to functional assays.

• Discovery Biology: Ensures sample integrity for validating PD-L1 or other immune checkpoint targets in lung cancer models.
• Screening: Delivers reproducible sections for antibody screening and biomarker quantification.
• Analytics: Generates quantifiable histological readouts for correlating target expression with drug response.
• Translational Research: Bridges cytology and tissue analysis, supporting biomarker continuity from early detection to preclinical validation.
• Enterprise Reuse: Establishes a transferable SOP for NSCLC specimen handling across discovery, translational, and preclinical teams.

Operational & Enterprise Impact

• Scientific Value: Reduces pre-analytical artifacts that could confound target expression data.
• Operational Value: Enables high-throughput processing of NSCLC biopsies and cytology samples.
• Strategic Value: Increases confidence in go/no-go decisions by ensuring reliable biomarker assessment.
• Portfolio Impact: Supports risk-stratified advancement of immuno-oncology candidates based on consistent histopathological data.

Implementation Considerations

• Histopathology expertise for proper fixation, embedding, and sectioning.
• Access to microtomes, tissue processors, and embedding stations.
• Standardized protocols for formalin concentration and paraffin infiltration times.
• Adaptation considerations for varying specimen sizes from biopsies versus cytology pellets.
• Quality control steps to assess section integrity and staining fidelity before downstream analysis.

Biopharma FAQs